Logo image
Sign in
Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement
Journal article   Peer reviewed

Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement

Ludger Klimek, Marek Jutel, Cezmi Akdis, Jean Bousquet, Mübeccel Akdis, Claus Bachert, Ioana Agache, Ignacio Ansotegui, Anna Bedbrook, Sinthia Bosnic-Anticevich, …
Allergy, Vol.75(7), pp.1546-1554
07/2020
PMCID: PMC7264744
PMID: 32329930

Abstract

allergy treatment immunotherapy clinical immunotherapy vaccines and mechanisms Allergists Asthma Infection Control Pandemics Pneumonia, Viral Rhinitis, Allergic SARS-CoV-2 Sublingual Immunotherapy Th2 Cells Betacoronavirus CD8-Positive T-Lymphocytes COVID-19 Coronavirus Infections Eosinophils Humans Immunoglobulin E Immunoglobulin M
The current COVID‐19 pandemic influences many areas of social life, medical treatments and the way allergy is performed. Allergen‐specific immunotherapy (AIT) is one of the most important treatment options for IgE‐mediated allergies and is based on immunological effects on the diseased patient.
url
Find in HALView

Details

Logo image